[{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA receptor A","graph1":"Neurology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Cassiopea","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Hyphens Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Cassiopea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Adalvo"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Termination","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Cosmo Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Winlevi (clascoterone) cream is a prescription medicine and an androgen receptor antagonist, used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.

                          Product Name : Winlevi

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 10, 2025

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Glenmark Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Winlevi (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age & older.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 10, 2023

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the terms of the agreement, Hikma will receive from Cosmo, the exclusive right to register and commercialize Winlevi (clascoterone) in African countries, which is indicated for acne vulgaris.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : $0.7 million

                          October 02, 2023

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Hikma Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the licensing agreement, Adalvo will receive from Cosmo the exclusive right to develop and commercialize Rifamycin SV MMX (rifamycin sodium) for the treatement of Travelers’ Diarrhea.

                          Product Name : Rifamycin SV MMX

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          September 04, 2023

                          Lead Product(s) : Rifamycin Sodium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Adalvo

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Cosmo terminates mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX (Rifamycin Sodium) in the EU and other selective countries.

                          Product Name : Rifamycin SV MMX

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          September 04, 2023

                          Lead Product(s) : Rifamycin Sodium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Dr. Falk Pharma

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : CB-03-01 (clascoterone) solution is an androgen receptor inhibitor which is currently being evaluated for the treatment of patients with androgenetic alopecia.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 29, 2023

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the license agreement terms, Hyundai Pharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in the Republic of Korea, which is indicated for acne vulgaris.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 22, 2023

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Hyundai Pharm

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : $1.0 million

                          December 21, 2022

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Hyphens Pharma

                          Deal Size : $5.0 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Rifamycin SV (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, being evaluated for the treatement of pouchitis.

                          Product Name : Rifamycin SV

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          October 20, 2022

                          Lead Product(s) : Rifamycin Sodium

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the license agreement terms, Infectopharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in Germany, Italy & Austria, which is indicated for acne vulgaris.

                          Product Name : Winlevi

                          Product Type : Small molecule

                          Upfront Cash : $0.9 million

                          October 04, 2022

                          Lead Product(s) : Clascoterone

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : InfectoPharm Drugs and Consilium

                          Deal Size : $4.4 million

                          Deal Type : Licensing Agreement

                          blank